Potential new targeted therapy for Duchenne muscular dystrophy
The U.S. Food and Drug Administration (FDA) recently granted accelerated approval for Sarepta Therapeutics’ golodirsen (Vyondys 53), an injection for…
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.